Manufacturer Supply, High Quality, Commercial Production
Chemical Name: 1-(1-Benzothiophen-4-yl)piperazine Hydrochloride
CAS: 913614-18-3
| Chemical Name |
1-(1-Benzothiophen-4-yl)piperazine Hydrochloride |
| Synonyms |
Brexpiprazole Intermediate 2; 1-Benzo[b]thien-4-yl-Piperazine Hydrochloride; 1-Benzo[b]thien-4-ylpiperazine Monohydrochloride |
| CAS Number |
913614-18-3 |
| CAT Number |
RF-PI1034 |
| Stock Status |
In Stock, Production Capacity 100MT/Year |
| Molecular Formula |
C12H15ClN2S |
| Molecular Weight |
254.7789 |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
| Appearance |
White to Off-White Powder |
| Identification |
Retention time of the sample conforms to that of the reference standard |
| Purity / Analysis Method |
>99.0% (HPLC) |
| Loss on Drying |
<0.50% |
| Water (K.F) |
<0.50% |
| Residue on Ignition |
<0.20% |
| Related Substances |
(HPLC) |
| Any Individual Impurity |
<0.50% |
| Total Impurities |
<1.00% |
| Infrared Spectrum |
Conforms to Structure |
| Proton NMR Spectrum |
Conforms to Structure |
| Test Standard |
Enterprise Standard |
| Usage |
Intermediate of Brexpiprazole (CAS: 913611-97-9) |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture
1-(1-Benzothiophen-4-yl)piperazine Hydrochloride (CAS: 913614-18-3) is an intermediate of Brexpiprazole (CAS: 913611-97-9). Brexpiprazole is a kind of atypical antipsychotic. It is a dopamine D2 receptor partial agonist. As a novel serotonin-dopamine activity modulator, it can be used for the treatment of schizophrenia, and for the adjunctive treatment for depression. It can also provide efficacy and tolerability over established adjunctive treatments formajor depressive disorder(MDD). The drug exhibits a unique pharmacological profile, acting as a partial agonist of serotonin 5-HT1A and dopamine D2 receptors and as a full antagonist of 5-HT2A and noradrenaline α1B/2C receptors, with similar subnanomolar binding affinity. The drug, which was developed by Otsuka and Lundbeck, was approved in 2015 by the FDA for the treatment of schizophrenia and as an adjunctive treatment for depression.